I am delighted to announce that we just released our global guide to managing clinical trials during the COVID-19 pandemic. Our report covers more than 40 jurisdictions across five continents and we will be updating its contents, and adding more countries, on a regular basis.
The unprecedent situation resulting from the COVID-19 pandemic impacts the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address multiple challenges to ensure the continuity of trials on human medicines. Many countries have introduced local lockdown measures, which affect trial site accessibility. In addition, limited availability of medical staff and disruptions in global supply chain raise questions around the provision of investigational medicinal products (IMPs) or modifications to clinical trials protocols.